SEC Form SC14D9C filed by Turnstone Biologics Corp.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934
(Amendment No. )
Turnstone Biologics Corp.
(Name of Subject Company)
Turnstone Biologics Corp.
(Name of Persons Filing Statement)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
90042W100
(CUSIP Number of Class of Securities)
Sammy Farah, M.B.A., Ph.D.
President and Chief Executive Officer
Turnstone Biologics Corp.
9310 Athena Circle, Suite 300
La Jolla, California 92037
(347) 897-5988
(Name, address, and telephone number of person authorized to receive notices and communications
on behalf of the persons filing statement)
With a copy to:
Divakar Gupta
Rama Padmanabhan
Courtney Tygesson
Cooley LLP
55 Hudson Yards
New York, New York 10001
(212) 479-6000
| ☒ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
This Schedule 14D-9 filing consists of the following communication related to the proposed acquisition of Turnstone Biologics Corp., a Delaware corporation (the “Company”), pursuant to the terms of an Agreement and Plan of Merger, dated as of June 26, 2025, by and among the Company, XOMA Royalty Corporation, a Nevada corporation (“XOMA”), and XRA 3 Corp., a Delaware corporation and a wholly-owned subsidiary of XOMA:
| • | Press Release of Turnstone Biologics Corp. dated June 27, 2025 (Exhibit 99.1) |